Adjunctive Nicorandil Ameliorates Cardiac Function and Clinical Outcomes Following Recombinant Human Pro-Urokinase Thrombolysis in Patients With Acute ST-Segment Elevation Myocardial Infarction
Annals of Pharmacotherapy · 21.11.2026
DOI: 10.1177/10600280261502354 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 21.11.2026. Verfasst von Fuyi Liu und 3 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Background
Recombinant human pro-urokinase (rhPro-UK) is a primary reperfusion strategy for acute ST-segment elevation myocardial infarction (STEMI). This study evaluated the clinical efficacy and safety of adjunctive nicorandil therapy alongside rhPro-UK intravenous thrombolysis in patients with STEMI.
Objective
This study aimed to investigate the clinical application value of nicorandil combined with recombinant human prourokinase in patients with acute STEMI receiving intravenous thrombolysis.
Methods
This retrospective cohort study included 116 patients with STEMI (June 2024-March 2026). Patients were divided into a control group (rhPro-UK, n = 54) and an observation group (rhPro-UK plus nicorandil, n = 62). We compared reperfusion success rates, ST-segment resolution at 2 hours, and cardiac biomarker levels (cardiac troponin I [cTnI], creatine kinase-MB [CK-MB]) at baseline and 24 hours post-thrombolysis. Left ventricular function (left ventricular ejection fraction [LVEF], left ventricular end-diastolic diameter [LVEDD]) was assessed on day 7. Clinical safety, including incidence of serious arrhythmias, major adverse cardiovascular events (MACE) within 30 days, and adverse drug reactions, was systematically monitored.
Results
The observation group achieved significantly higher rates of successful reperfusion (79.03% vs 61.11%) and ST-segment resolution (74.19% vs 55.56%) compared with the control group ( P < .05). At 24 hours, the observation group exhibited lower cTnI and CK-MB levels and earlier peak CK-MB timing ( P < .05). On day 7, patients treated with nicorandil showed superior LVEF and smaller LVEDD ( P < .05). Furthermore, the observation group experienced fewer serious arrhythmias and lower 30-day MACE rates ( P < .05). No significant difference in adverse drug reactions was observed between cohorts ( P > .05). Conclusion and Relevance: Adjunctive nicorandil enhances the efficacy of rhPro-UK thrombolysis, mitigating myocardial injury and improving early cardiac function. This combination therapy reduces short-term cardiovascular risk without increasing adverse reactions, demonstrating favorable clinical safety and utility in STEMI management.
Zitieren
APA
Liu, F., He, Q., Luo, L., & Mu, Q. (2026). Adjunctive Nicorandil Ameliorates Cardiac Function and Clinical Outcomes Following Recombinant Human Pro-Urokinase Thrombolysis in Patients With Acute ST-Segment Elevation Myocardial Infarction. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280261502354
Vancouver
Liu F, He Q, Luo L, Mu Q. Adjunctive Nicorandil Ameliorates Cardiac Function and Clinical Outcomes Following Recombinant Human Pro-Urokinase Thrombolysis in Patients With Acute ST-Segment Elevation Myocardial Infarction. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280261502354
BibTeX
@article{Liu2026,
author = {Liu, Fuyi and He, Qian and Luo, Luling and Mu, Qiong},
title = {Adjunctive Nicorandil Ameliorates Cardiac Function and Clinical Outcomes Following Recombinant Human Pro-Urokinase Thrombolysis in Patients With Acute ST-Segment Elevation Myocardial Infarction},
journal = {Annals of Pharmacotherapy},
year = {2026},
doi = {10.1177/10600280261502354}
}
EUVIMED